Molecule to Market takes you inside the contract outsourcing space with industry insights and thoughts direct from the brains of the people that make the headlines (just think of your favourite podcast and that’s what we’re doing, but with drug supply chain shortages instead of unsolved crimes and life science leaders instead of sports stars). Talking everything from pharmaceutical contract research, development and manufacturing to clinical trial packaging, logistics and technology – Molecule to Market is a vital shot of infotainment for anyone who wants in on outsourcing.
All content for Molecule to Market: Inside the outsourcing space is the property of Raman Sehgal and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Molecule to Market takes you inside the contract outsourcing space with industry insights and thoughts direct from the brains of the people that make the headlines (just think of your favourite podcast and that’s what we’re doing, but with drug supply chain shortages instead of unsolved crimes and life science leaders instead of sports stars). Talking everything from pharmaceutical contract research, development and manufacturing to clinical trial packaging, logistics and technology – Molecule to Market is a vital shot of infotainment for anyone who wants in on outsourcing.
In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Adam Sherlock, CEO at Qinecsa.
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Adam, covering:
How he developed his professional CEO skills over the years to complement is entrepreneurial spirit
The combination of micro and macro factors that help determine when the right time is to go to market, and sell
The importance of your gut instinct when assessing M&A targets... and painting a picture of why the world is a better place when together
Several attempts at failing to retire... and being tempted back into another pharma services CEO role
How R&D services will be impacted by AI, and why we all need to be eating our own lunch
Adam is a serial entrepreneur and executive leader with nearly 40 years of experience in the international life sciences industry, particularly in bio/pharma, IVD, and medical device sectors. A scientist by training, he has led successful growth and M&A efforts, creating exceptional value in four private equity-backed businesses over the past decade.
Adam is also a sought-after NED, Chair, and independent advisor. Currently, he serves as CEO of Qinecsa, a global provider of pharmacovigilance technology and services.
Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
Molecule to Market is also sponsored by Bora Pharma (boracdmo.com) and Charles River (www.criver.com), and supported by ramarketing.
Molecule to Market: Inside the outsourcing space
Molecule to Market takes you inside the contract outsourcing space with industry insights and thoughts direct from the brains of the people that make the headlines (just think of your favourite podcast and that’s what we’re doing, but with drug supply chain shortages instead of unsolved crimes and life science leaders instead of sports stars). Talking everything from pharmaceutical contract research, development and manufacturing to clinical trial packaging, logistics and technology – Molecule to Market is a vital shot of infotainment for anyone who wants in on outsourcing.
